title: Optimal use of antibiotic resistance surveillance systems.
abstract: Increasing concern about the emergence of resistance in clinically important pathogens has led to the establishment of a number of surveillance programmes to monitor the true extent of resistance at the local, regional and national levels. Although some programmes have been operating for several years, their true usefulness is only now being realised. This review describes some of the major surveillance initiatives and the way in which the data have been used in a number of different settings. In the hospital, surveillance data have been used to monitor local antibiograms and determine infection control strategies and antibiotic usage policies. In the community, surveillance data have been used to monitor public health threats, such as infectious disease outbreaks involving resistant pathogens and the effects of bioterrorism countermeasures, by following the effects of prophylactic use of different antibiotics on resistance. Initially, the pharmaceutical industry sponsored surveillance programmes to monitor the susceptibility of clinical isolates to marketed products. However, in the era of burgeoning resistance, many developers of antimicrobial agents find surveillance data useful for defining new drug discovery and development strategies, in that they assist with the identification of new medical needs, allow modelling of future resistance trends, and identify high-profile isolates for screening the activity of new agents. Many companies now conduct pre-launch surveillance of new products to benchmark activity so that changes in resistance can be monitored following clinical use. Surveillance data also represent an integral component of regulatory submissions for new agents and, together with clinical trial data, are used to determine breakpoints. It is clear that antibiotic resistance surveillance systems will continue to provide valuable data to health care providers, university researchers, pharmaceutical companies, and government and regulatory agencies.
authors.affiliation: Replidyne, Inc, Louisville, CO 80027, USA. icritchley@replidyne.com
authors.forename: I A
authors.initials: IA
authors.lastname: Critchley
authors.forename: J A
authors.initials: JA
authors.lastname: Karlowsky
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology; D001419:Bacteria / Q000187:drug effects; D024881:Drug Resistance, Bacterial; D006077:Government Agencies; D006801:Humans; D008826:Microbial Sensitivity Tests / Q000379:methods / Q000592:standards / Q000706:statistics & numerical data*; D011159:Population Surveillance / Q000379:methods*; D017149:Private Sector; D014481:United States
chemical_list: D000900:Anti-Bacterial Agents